BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder



Status:Completed
Conditions:Depression, Depression, Major Depression Disorder (MDD)
Therapuetic Areas:Psychiatry / Psychology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - 65
Updated:3/29/2019
Start Date:June 12, 2017
End Date:December 12, 2018

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Study Of BTRX-246040 Administered Once Daily In Patients With Major Depressive Disorder With Or Without Anhedonia

This study will determine the efficacy, safety, and tolerability of a once-daily (QD) dose of
up to 80 mg of BTRX-246040 for 8 weeks in participants with MDD.


Inclusion Criteria:

- Patients with a diagnosis of MDD as defined by DSM-5 criteria and have had at least 1
prior major depressive episode in the past 10 years

- Patients must present with a new current episode of MDD and the duration of the
current episode must be at least 4 weeks but not longer than 18 months.

- At Visit 1 (screening) and Visit 2 (baseline), patients must have clinically
significant depressive symptoms defined by tandem (investigator- and
computer-administered) Montgomery-Asberg Depression Rating Scale (MADRS) total scores
≥ 26 with a difference of ≤ 7 points between the Investigator- and
computer-administered MADRS total scores

- Patients must have a CGI-S score ≥ 4 at Visit 2 (baseline).

Exclusion Criteria:

- Patients who present with any current DSM-5 disorder other than MDD which is the focus
of treatment.

- Patients who are homicidal in the opinion of the Investigator or are at suicidal risk
(any suicide attempts within 12 months prior to Visit 1 [screening] or any suicidal
intent, including a plan, within 3 months prior to Visit 1 [screening]; C-SSRS answer
of "YES" on item 4 or 5 [suicidal ideation]; Investigator- or computer-administered
MADRS score of ≥ 5 on item 10 [suicidal thoughts]; by Investigator clinical
evaluation).

- Patients cannot have any history of substance or alcohol use disorder within 12 months
prior to Visit 1 (screening) per DSM-5 criteria

- Patients must not have a clinically significant comorbid disease.
We found this trial at
8
sites
Libertyville, Illinois 60048
Phone: 847-549-7214
?
mi
from
Libertyville, IL
Click here to add this to my saved trials
Cerritos, California 90703
Phone: 562-246-3800
?
mi
from
Cerritos, CA
Click here to add this to my saved trials
Garden Grove, California 92845
Phone: 714-799-7799
?
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Jacksonville, Florida 32256
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Lauderhill, Florida 33319
Phone: 954-990-6326
?
mi
from
Lauderhill, FL
Click here to add this to my saved trials
Memphis, Tennessee 38119
Phone: 901-843-1045
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Orlando, Florida 32801
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Rochester, New York 14618
?
mi
from
Rochester, NY
Click here to add this to my saved trials